Christopher E.M. Griffiths

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Disease
• Gene

His primary areas of investigation include Psoriasis, Internal medicine, Dermatology, Immunology and Surgery. Christopher E.M. Griffiths combines subjects such as Quality of life and Disease with his study of Psoriasis. His Internal medicine research incorporates elements of Gastroenterology, Placebo and Endocrinology.

Tretinoin and Negroid is closely connected to Chemotherapy in his research, which is encompassed under the umbrella topic of Dermatology. His studies in Surgery integrate themes in fields like Cohort study, Confidence interval and Ustekinumab. His study in Guselkumab is interdisciplinary in nature, drawing from both Etanercept and Risankizumab.

His most cited work include:

• Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence (1192 citations)
• Secukinumab in plaque psoriasis--results of two phase 3 trials. (1146 citations)
• Pathogenesis and clinical features of psoriasis. (1130 citations)

What are the main themes of his work throughout his whole career to date?

Psoriasis, Internal medicine, Dermatology, Immunology and Pathology are his primary areas of study. His study in Psoriasis focuses on Psoriasis Area and Severity Index in particular. His Psoriasis Area and Severity Index research is multidisciplinary, relying on both Dermatology Life Quality Index, Adverse effect and Severity of illness.

His Internal medicine study integrates concerns from other disciplines, such as Placebo, Endocrinology and Surgery. Christopher E.M. Griffiths works mostly in the field of Endocrinology, limiting it down to topics relating to Human skin and, in certain cases, Retinoic acid, as a part of the same area of interest. Christopher E.M. Griffiths has researched Dermatology in several fields, including Chemotherapy and MEDLINE.

He most often published in these fields:

• Psoriasis (60.87%)
• Internal medicine (29.12%)
• Dermatology (23.45%)

What were the highlights of his more recent work (between 2018-2021)?

• Psoriasis (60.87%)
• Internal medicine (29.12%)
• MEDLINE (8.83%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Psoriasis, Internal medicine, MEDLINE, Psoriasis Area and Severity Index and Dermatology. The study incorporates disciplines such as Clinical trial, Intensive care medicine, Disease, Etanercept and Cohort in addition to Psoriasis. He usually deals with Disease and limits it to topics linked to General partnership and Systematic review and Nursing.

His MEDLINE research incorporates themes from Global health, Physiology, Seasonality and Circadian rhythm. His Psoriasis Area and Severity Index study combines topics in areas such as Odds ratio, Dermatology Life Quality Index, Adverse effect and Dosing. In his study, Gastroenterology is strongly linked to Moderate to severe, which falls under the umbrella field of Dermatology.

Between 2018 and 2021, his most popular works were:

• Clinical applications of machine learning algorithms: beyond the black box. (84 citations)
• HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (41 citations)
• Clinical and genetic differences between pustular psoriasis subtypes (38 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Gene
• Disease

His primary scientific interests are in Psoriasis, Internal medicine, Psoriasis Area and Severity Index, Cohort and Ustekinumab. His study deals with a combination of Psoriasis and Systemic therapy. Christopher E.M. Griffiths interconnects Dermatology Life Quality Index, Bioinformatics, Transcriptome, Randomized controlled trial and Confidence interval in the investigation of issues within Psoriasis Area and Severity Index.

He combines subjects such as Placebo and Interleukin 17 with his study of Randomized controlled trial. The study incorporates disciplines such as Dermatology, Acrodermatitis, Therapeutic drug monitoring and Cohort study in addition to Cohort. His work focuses on many connections between Ustekinumab and other disciplines, such as Clinical trial, that overlap with his field of interest in Propensity score matching and Number needed to treat.